



**LIETUVOS RESPUBLIKOS NUOLATINĖ ATSTOVYBĖ PRIE
JUNGTINIŲ TAUTŲ BIURO IR KITŲ TARPTAUTINIŲ ORGANIZACIJŲ
ŽENEVOJE**

**MISSION PERMANENTE DE LA LITUANIE
AUPRÈS DE L'OFFICE DES NATIONS UNIES ET
DES AUTRES ORGANISATIONS INTERNATIONALES À GENÈVE**

No. SN-57 / 2013

The Permanent Mission of the Republic of Lithuania to the United Nations Office and Other International Organisations at Geneva presents its compliments to the United Nations Office for Disarmament Affairs Geneva Branch acting as Secretariat of the Meetings of the Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on Their Destruction and has the honour to submit the enclosed herewith annual Confidence-Building Measures for the year 2012 under the Convention by the Republic of Lithuania. The electronic version of the submission is being sent to the BWC Implementation Support Unit. As in the previous seven years, Lithuania would like this submission to be published publicly.

The Permanent Mission of the Republic of Lithuania to the United Nations Office and Other International Organizations at Geneva avails itself of this opportunity to reiterate to the United Nations Office for Disarmament Affairs Geneva Branch the assurances of its highest consideration.



Geneva, 15 April 2013

TO THE UNITED NATIONS
OFFICE FOR DISARMAMENT AFFAIRS
GENEVA BRANCH
Geneva

ENCLOSURE. National submission in 8 pages.

**DECLARATION FORM ON NOTHING TO DECLARE OR NOTHING NEW TO
DECLARE FOR USE IN THE INFORMATION EXCHANGE**

| Measure | Nothing to declare | Nothing new to declare |
|-----------------|-------------------------------------|-------------------------------------|
| A, part I | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| A, part 2 (i) | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| A, part 2 (ii) | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| A, part 2 (iii) | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| B (i) | <input type="checkbox"/> | <input type="checkbox"/> |
| B (ii) | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| C | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| D | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| E | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| F | <input checked="" type="checkbox"/> | <input type="checkbox"/> |
| G | <input type="checkbox"/> | <input checked="" type="checkbox"/> |

(Please mark the appropriate box(es) for each measure, with a tick.)

Date: **11 April 2013**

State Party to the Convention: **Republic of Lithuania**

CONFIDENCE BUILDING MEASURE A (Part I)

Form A, part 1

Exchange of data on research centres and laboratories¹

1. Name(s) of facility²

National Public Health Surveillance Laboratory

2. Responsible public or private organization or company

Ministry of Health

3. Location and postal address

Zolyno Str. 36, LT-10210 Vilnius, Lithuania

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

Ministry of Health

5. Number of maximum containment units³ within the research centre and/or laboratory, with an indication of their respective size (m²)

None

6. If no maximum containment unit, indicate highest level of protection

Level 3

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Personal and public health purposes: diagnosis of bacterial infectious diseases such as Anthrax, Tularaemia, Plague, Brucellosis, Cholera, Legionellosis, other Food- and Waterborne Diseases, Botulism, etc.

HIV, HTLV, enteroviruses and poliomyelitis, influenza and parainfluenza, measles, rubella, herpes infections, viral haemorrhagic fevers, parasitoses, tick born diseases, etc.

¹The containment units which are fixed patient treatment modules, integrated with laboratories, should be identified separately.

²For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

³In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

1. Name(s) of facility⁴

National Food and Veterinary Risk Assessment Institute

2. Responsible public or private organization or company

State Food and Veterinary Service

3. Location and postal address

J. Kairiukscio Str. 10, LT-08409 Vilnius, Lithuania

4. Source(s) of financing of the reported activity, including indication if the activity is wholly or partly financed by the Ministry of Defence

State Food and Veterinary Service

5. Number of maximum containment units⁵ within the research centre and/or laboratory, with an indication of their respective size (m²)

None

6. If no maximum containment unit, indicate highest level of protection

Level 3

7. Scope and general description of activities, including type(s) of micro-organisms and/or toxins as appropriate

Rabies, Highly pathogenic avian influenza, Newcastle disease, Leptospirosis, Anthrax, Foot and mouth disease, Swine vesicular disease, Bluetongue, African horse sickness, African swine fever, Classical swine fever (hog cholera), Tuberculosis, Brucellosis, Salmonellosis, Listeriosis, Vibriosis, Campylobacteriosis, Yersiniosis, Shigellosis, Toxoplasmosis, Trichinellosis, and other viral, parasitological and bacterial diseases of animals

⁴For facilities with maximum containment units participating in the national biological defence research and development programme, please fill in name of facility and mark "Declared in accordance with Form A, part 2 (iii)".

⁵In accordance with the 1983 WHO Laboratory Biosafety Manual, or equivalent

Form A, part 2 (i)

National biological defence research and development programme Declaration

Is there a national programme to conduct biological defence research and development within the territory of the State Party, under its jurisdiction or control anywhere? Activities of such a programme would include prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination and other related research.

No

If the answer is Yes, complete Form A, part 2 (ii) which will provide a description of the programme.

Form A, part 2 (ii)

National biological defence research and development programme

NSTR

Form A, part 2 (iii)

National biological defence research and development programme

NSTR

Form B (i)

Background information on outbreaks of reportable infectious diseases

This is in accordance with the WHO International Statistical Classification of Diseases and Related Health Problems, 10th Revision

Certain infectious and parasitic diseases in Lithuania for 2012

WHO Classification of

Disease

Case per year

(1) Human diseases (number of cases per year)

| Diseases | 2011 | 2012 |
|--------------------|------|------|
| AIDS | 20 | 38 |
| Amebiasis | 11 | 15 |
| Botulism | 3 | 1 |
| Brucellosis | 0 | 0 |
| Campylobacteriosis | 848 | 917 |

| | | |
|-------------------------------------|--|--|
| Chancroid | not reported | Not reported |
| Chicken-pox | 14193 | 17546 |
| Chlamydial infections | 343 | 265 |
| Cholera | 0 | 0 |
| Diphtheria | 1 | 0 |
| Giardiasis | 8 | 13 |
| Gonococcal infections | 248 | 219 |
| Gonococcal ophthalmia neonatorum | not reported | Not reported |
| H.Influenzae B (invasive) | 3 | 3 |
| Hepatitis A | 17 | 113 |
| Hepatitis B | 60 | 23 |
| Hepatitis C | 43 | 40 |
| Hepatitis non A-non B | 3 | |
| Hepatitis other unspecified viral? | 0 | 0 |
| Legionellosis | 2 | 9 |
| Leprosy | 0 | 0 |
| Listeriosis | 6 | 8 |
| Malaria | 3 | 6 |
| Measles | 7 | 2 |
| Pneumococcal meningitis | 9 | 7 |
| Other bacterial meningitis | 33 | 42 |
| Viral meningitis | 137 | 180 |
| Meningococcal infections | 80 | 83 |
| Mumps | 64 | 62 |
| Paratyphoid | 2 | 0 |
| Pertussis | 30 | 154 |
| Plague | 0 | 0 |
| Poliomelitis | 0 | 0 |
| Rabies | 0 | 0 |
| Rubella | 0 | 0 |
| Congenital rubella | 0 | 0 |
| Salmonellosis | 2073 | 1584 |
| Shigellosis | 40 | 52 |
| Syphilis, Congenital | 0 | 1 |
| Syphilis, Early Latern | 273 | 227 |
| Other Syphilis | Is included into Syphilis, Early Latern | Is included into Syphilis, Early Latern |
| Tetanus | 2 | 2 |
| Trichinelosis | 51 | 30 |
| Tuberculosis | 1033 | 1048 |
| Typhoid fever | 1 | 2 |
| Verotoxigenic E.coli infection 0157 | 1 | 0 |
| Yellow Fever | 0 | 0 |

Background information on outbreaks of reportable infectious diseases

(2) Human diseases (outbreaks)

| Diseases | 2011 | 2012 |
|--------------------------------------|-------------|-------------|
| Shigellosis | 3 | 5 |
| Salmonellosis | 67 | 51 |
| Trichinellosis | 4 | 8 |
| Staphylococcal infection (S. aureus) | 0 | 0 |
| Tick-borne encephalities | 0 | 0 |
| Rotoviral infection | 148 | 127 |
| Not confirmed etiology | 197 | 152 |

Form B (ii)

Information on outbreaks of infectious diseases and similar occurrences, that seem to deviate from the normal pattern

NSTR

Form C

Encouragement of publication of results and promotion of use of knowledge

NSTR

Form D

Active promotion of contacts

1. **Planned international conferences, symposia, seminars, and other similar forums for exchange**

NSTR

2. **Information regarding other opportunities**

NSTR

Form E

Declaration of legislation, regulations and other measures

| Relating to | Legislation | Regulations | Other Measures | Amended since last year |
|--|-------------|-------------|----------------|-------------------------|
| a) development, production, stockpiling, acquisition, or retention of microbial or other biological agents, or toxins, weapons, equipment and means of delivery specified in Article I | YES | YES | YES | NO |
| b) exports of micro-organisms* and toxins | YES | YES | YES | NO |
| c) imports of micro-organisms* and toxins | YES | YES | YES | NO |

* Micro-organisms pathogenic to man, animals and plants in accordance with the Convention

Declaration of past activities in offensive and/or defensive biological research and development programmes

1. Date of entry into force of the Convention for the State party.

10 April 1997

2. Past offensive biological research and development programmes:

- **NO**
- Period(s) of activities
- Summary of the research and development activities indicating whether work was performed concerning production, test and evaluation, weaponization, stockpiling of biological agents, the destruction programme of such agents and weapons, and other related research.

3. Past defensive biological research and development programmes:

- **NO**
- Period(s) of activities
- Summary of the research and development activities indicating whether or not work was conducted in the following areas: prophylaxis, studies on pathogenicity and virulence, diagnostic techniques, aerobiology, detection, treatment, toxinology, physical protection, decontamination, and other related research, with location if possible.

Declaration of vaccine production facilities

No vaccines are produced in Lithuania